garenoxacin has been researched along with ENT Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuda, H | 1 |
| Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N | 2 |
1 review(s) available for garenoxacin and ENT Diseases
| Article | Year |
|---|---|
[Pharmacological properties and clinical efficacy of garenoxacin mesilate hydrate (Geninax Tablet 200 mg), a quinolone antimicrobial].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteria; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Humans; Otorhinolaryngologic Diseases; Respiratory Tract Infections; Tablets; Therapeutic Equivalency | 2008 |
2 other study(ies) available for garenoxacin and ENT Diseases
| Article | Year |
|---|---|
[Antimicrobial susceptibility surveillance of recent isolates from otorhinolaryngological infections to garenoxacin and other antimicrobial drugs].
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Positive Cocci; Humans; Otorhinolaryngologic Diseases; Time Factors | 2009 |
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2010 |